Categories AlphaGraphs, Earnings, Technology

Earnings: Cisco (CSCO) Q3 2023 profit grows on higher revenues

Cisco Systems Inc. (NASDAQ: CSCO) announced results for the third quarter of 2023, reporting higher revenues and earnings. The company also provided guidance for the fourth quarter and fiscal 2023.

Cisco Q3 2023 earnings infographic

The San Jose-headquartered network gear maker said that earnings, excluding special items, rose to $1.00 per share in the April quarter from $0.87 per share in the same period of 2022. Unadjusted net income was $3.21 billion or $0.78 per share, compared to last year’s profit of $3.04 billion or $0.73 per share.

At $14.57 billion, third-quarter revenues were up 14% year-over-year. The top line benefitted from strong contributions from the core Secure, Agile Networks division.

“In Q3, we delivered record revenue and double-digit growth in both software and subscription revenue. As key technologies like cloud, AI and security continue to scale, Cisco’s long-established leadership in networking, and the breadth of our portfolio position us well for the future,” said Cisco’s CEO Chuck Robbins.

Prior Performance

  • Cisco Q2 2023 earnings infographic
  • Cisco-Q1-2023-Earnings-Infographic
  • Cisco Q4 2022 earnings infographic
  • Cisco Q3 2022 earnings infographic

_________________________________________________________________________________________________________________

Stocks you may like:

Apple (AAPL) Stock

Microsoft (MSFT) Stock

Alphabet (GOOGL) Stock

International Business Machines Corp. (IBM) Stock

_________________________________________________________________________________________________________________

Most Popular

Key takeaways from JM Smucker’s (SJM) Q4 2025 earnings report

Shares of The J.M. Smucker Co. (NYSE: SJM) plunged 15% on Tuesday after the company delivered mixed results for the fourth quarter of 2025. While earnings came ahead of expectations,

J.M. Smucker (SJM) Q4 2025 Earnings: Key financials and quarterly highlights

The J.M. Smucker Co. (NYSE: SJM) reported its fourth quarter 2025 earnings results today. Net sales was $2.1 billion, down 3% year-over-year. Comparable net sales decreased 1%. Net loss was

Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials

Plus Therapeutics (NASDAQ: PSTV) is a pharmaceutical company engaged in the development of targeted radiotherapeutics for difficult-to-treat cancers. Currently, it is advancing a pipeline of product candidates with lead programs

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top